Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Alterity Therapeutics AAN Presentation 5 May 2019

May 6, 2019May 27, 2019 Alterity Therapeutics

Alterity Therapeutics AAN Presentation 5 May 2019 Download

Post navigation

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting

Alterity Therapeutics commences US investor meetings following positive clinical data

Related Posts

Prana receives $3 million R&D Tax Incentive Refund

December 19, 2017

Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

May 26, 2022May 26, 2022

World leader in movement disorders Professor Ira Shoulson joins Prana board

May 13, 2014

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065